Stryker Corporation (NYSE:SYK) Receives Average Rating of “Moderate Buy” from Analysts

Stryker Corporation (NYSE:SYK) has received a consensus rating of “Moderate Buy” from the twenty-three brokerages that are covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $392.5217.

SYK has been the topic of a number of recent research reports. Argus set a $370.00 target price on Stryker in a research report on Thursday, July 9th. The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 price target on shares of Stryker in a research report on Friday, May 1st. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Truist Financial reaffirmed a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Finally, Evercore set a $350.00 price objective on shares of Stryker in a research note on Monday, July 6th.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. The trade was a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 in the last quarter. 4.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Stryker

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Stryker by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after purchasing an additional 133,892 shares during the period. State Street Corp grew its position in Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after buying an additional 311,507 shares during the period. Geode Capital Management LLC increased its holdings in Stryker by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after buying an additional 69,851 shares in the last quarter. Wellington Management Group LLP increased its holdings in Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after buying an additional 1,198,665 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Stryker in the fourth quarter worth about $1,822,272,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Performance

Shares of SYK opened at $330.69 on Monday. The stock has a 50-day moving average of $314.69 and a two-hundred day moving average of $335.57. Stryker has a one year low of $281.00 and a one year high of $404.14. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock has a market cap of $126.77 billion, a P/E ratio of 38.27, a P/E/G ratio of 2.12 and a beta of 0.77.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts predict that Stryker will post 14.99 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.